8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

________________

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 30, 2005

E-Z-EM, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

1-11479	11-1999504
(Commission File Number)	(IRS Employer Identification No.)

1111 Marcus Avenue, Lake Success, New York	11042
(Address of Principal Executive Offices)	(Zip Code)

(516) 333-8230

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

(d) On March 30, 2005, the Board of Directors of E-Z-EM, Inc. (the "Company") approved a resolution authorizing and directing the officers of the Company to effect the listing of the Company's common stock on The Nasdaq National Market and to withdraw the listing of the Company's common stock from the American Stock Exchange. On March 31, 2005, the Company issued a press release announcing the Board's action, and that the Company's common stock is to begin trading on The Nasdaq National Market on April 12, 2005 and will continue to trade on the American Stock Exchange until that date. A copy of the press release dated March 31, 2005 is attached as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1 Press release dated March 31, 2005.

2

SIGNATURES:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 5, 2005	E-Z-EM, INC. (Registrant)
	By:    /s/ Peter J. Graham
	Peter J. Graham           Vice President - General Counsel and           Secretary

3

EXHIBIT INDEX

No. Description

99.1 Press Release dated March 31, 2005

EX-99.1

Exhibit 99.1

Company Contacts:	Investor Relations Contacts:
E-Z-EM, Inc.	Lippert/Heilshorn & Associates, Inc.
Tom Johnson (tjohnson@ezem.com)	Kim Sutton Golodetz (kgolodetz@lhai.com)
(800) 544-4624 x3317	(212) 838-3777
www.ezem.com	Bruce Voss (bvoss@lhai.com)
	(310) 691-7100

FOR IMMEDIATE RELEASE

E-Z-EM BOARD OF DIRECTORS APPROVES

LISTING ON NASDAQ NATIONAL MARKET

Lake Success, New York, March 31, 2005—E-Z-EM, Inc., (AMEX: EZM) today announced that its Board of Directors has approved the decision to switch the listing of the Company’s common stock from the American Stock Exchange to The Nasdaq National Market. Effective Tuesday, April 12, 2005, the Company’s common stock will begin trading under the symbol Nasdaq: EZEM. The Company’s common stock will continue to trade on the American Stock Exchange until the effective date.

Commenting on the announcement, Paul S. Echenberg, Chairman of the E-Z-EM Board of Directors, said, “This decision was reached after careful consideration of the capital market alternatives. We believe that trading on The Nasdaq National Market will allow us to increase the liquidity of our stock and increase the visibility of the Company, while at the same time providing investors with the best prices, the fastest execution, and the lowest cost per trade. This is an important achievement and milestone for E-Z-EM, and part of our ongoing efforts to maximize shareholder value. We have been extremely pleased with the professionalism of the American Stock Exchange, and we extend our thanks to the AMEX staff and to our specialist for their years of service.”

About E-Z-EM, Inc.

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company recently introduced VoLumenI® the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and PET/CT studies. It also offers the only family of CT injectors on the market, EmpowerCT® with patented EDA(TM) technology, that can help detect contrast extravasation, and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system.

The statements made in this document contain certain forward-looking statements. Words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates” or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company’s control. Such risks and uncertainties include, the Company’s ability to realize any benefits resulting from the listing of the Company’s common stock on The Nasdaq National Market, including but not limited to increased liquidity, resultant stock price and trading volume, trading execution and trading costs; the ability of the Company to develop its products, market acceptance, future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended November 27, 2004 and its Annual Report on Form 10-K for the fiscal year ended May 29, 2004. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.